<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2022000300007</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2022000300007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El sodio como excipiente de medicamentos y su potencial relación con la elevación de la presión arterial]]></article-title>
<article-title xml:lang="en"><![CDATA[Sodium as a drug excipient and its potential relationship with blood pressure elevation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lizano-Díez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bendahan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lastra]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mariño]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Modamio]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Barcelona Facultad de Farmacia y Ciencias de la Alimentación Unidad de Farmacia Clínica y Atención Farmacéutica. Departamento de Farmacia, y Tecnología Farmacéutica, y Fisicoquímica]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Institut Català de la Salut Servicio de Atención Primaria Esquerra de Barcelona ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>32</volume>
<numero>3</numero>
<fpage>249</fpage>
<lpage>254</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2022000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivos: Conocer la composición cuantitativa de sodio en las formas farmacéuticas efervescentes y en soluciones de analgésicos, suplementos de calcio y mucolíticos utilizadas crónicamente; evaluar en qué proporción se tiene en cuenta el potencial riesgo a la hora de prescribir estos medicamentos a pacientes hipertensos y analizar si la toma de estas formas farmacéuticas por la población hipertensa se acompañaba de una descompensación de los valores de presión arterial (PA).  Métodos: Se calculó el porcentaje de hipertensos tratados con paracetamol, calcio y acetilcisteína efervescentes (bicarbonato y carbonato sódico) en 10 Centros de Atención Primaria. Se realizó un estudio de cohortes retrospectivo con grupo control (ajustado por edad y género) en uno de los centros; seguimiento de un año. Las variables estudiadas fueron: PA sistólica (PAS) y diastólica (PAD) pre-post inicio del tratamiento con las formas farmacéuticas efervescentes, considerando clínicamente relevantes incrementos &gt;5 mmHg; intensificación del tratamiento antihipertensivo.  Resultados: Un 7,7% (rango: 5,4%-9,9%) de pacientes hipertensos se trataron con los medicamentos efervescentes estudiados. El porcentaje de hipertensos que mostraron un aumento de PAS relevante fue significativamente superior en el grupo tratado con medicamentos efervescentes en comparación al del grupo control: 35,9% (IC 95% 27,2%44,6%) vs. 18,8% (IC 95% 12,7%-24,8%) y también respecto a la intensificación del tratamiento antihipertensivo, 46,6% (IC 95% 37,5%-55,6%) vs. 30% (IC 95% 22,9%37,1%).  Conclusiones: La sensibilización al potencial efecto adverso es muy variable. Los medicamentos efervescentes que incluyen carbonato-bicarbonato de sodio pueden incrementar la PA. El uso de las formas farmacéuticas efervescentes, especialmente en pacientes de riesgo, debe evitarse.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Aim: To know the quantitative composition of sodium in effervescent pharmaceutical forms and in solutions of analgesics, calcium supplements and mucolytics used chronically; to evaluate in what proportion the potential risk is taken into account when prescribing these drugs to hypertensive patients and to analyze whether the taking of these pharmaceutical forms by the hypertensive population was accompanied by a decompensation of blood pressure (BP) values.  Methods: The percentage of hypertensive patients treated with effervescent paracetamol, calcium and acetylcysteine (bicarbonate and sodium carbonate) in 10 Primary Care Centers wascalculated. A retrospective cohort study with a control group (adjusted for ageand gender) was carried out in one of the centers. The follow-up was oneyear. The study variables were systolic (SBP) and diastolic (DBP) pre-post initiation of treatment with effervescent preparations, considering clinically relevant increases &gt;5 mmHg; intensification of antihypertensive treatment.  Results: 7.7% (range 5.4%-9.9%) of hypertensive patients were treated with the study effervescent drugs. The percentage of hypertensive patients who showed a relevant increase in SBP was significantly higher in the group treated with effervescent drugs compared to the control group: 35.9% (95% CI 27.2%-44.6%) vs. 18.8% (95% CI 12.7%-24.8%) and also regarding the intensification of antihypertensive treatment, 46.6% (95% CI 37.5%-55.6%) vs. 30% (95% CI 22.9%-37.1%).  Conclusions: Sensitivity to the potential adverse effect is highly variable. Effervescent medications that include sodium carbonate-bicarbonate can increase BP. The use of effervescent pharmaceutical forms, especially in patients at risk, should be avoided.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Medicamento]]></kwd>
<kwd lng="es"><![CDATA[excipiente]]></kwd>
<kwd lng="es"><![CDATA[sodio]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[atención primaria]]></kwd>
<kwd lng="es"><![CDATA[seguridad del paciente]]></kwd>
<kwd lng="en"><![CDATA[Drug]]></kwd>
<kwd lng="en"><![CDATA[excipient]]></kwd>
<kwd lng="en"><![CDATA[sodium]]></kwd>
<kwd lng="en"><![CDATA[high blood pressure]]></kwd>
<kwd lng="en"><![CDATA[primary care]]></kwd>
<kwd lng="en"><![CDATA[patient safety]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turck]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Castenmiller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Henauw]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch-Ernst]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Kearney]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<collab>EFSA Panel on Nutrition</collab>
<collab>Novel Foods and Food Allergens (NDA)</collab>
<article-title xml:lang=""><![CDATA[Dietary reference values for sodium]]></article-title>
<source><![CDATA[EFSA J]]></source>
<year>2019</year>
<volume>17</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Guideline: Sodium intake for adults andchildren]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turck]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Castenmiller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Henauw]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch-Ernst]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Kearney]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<collab>EFSA Panel on Nutrition</collab>
<collab>Novel Foods and Food Allergens (NDA)</collab>
<article-title xml:lang=""><![CDATA[Dietary reference values for chloride]]></article-title>
<source><![CDATA[EFSA J]]></source>
<year>2019</year>
<volume>17</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perrin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Korb-Savoldelli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Karras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Danchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Durieux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sabatier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk associated with high sodium-containing drugs: A systematic review]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2017</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Farquhar]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Influence of Dietary Salt Beyond Blood Pressure]]></article-title>
<source><![CDATA[Curr Hypertens Rep]]></source>
<year>2019</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<collab>Ministerio de Sanidad, Consumo y Bienestar Social</collab>
<source><![CDATA[Centro de información online de medicamentos de la AEMPS (CIMA)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="">
<collab>Institut Català de la Salut</collab>
<source><![CDATA[Memoria 2006]]></source>
<year>2006</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salt and prescribing behaviour: how a little bit of salt as a visualaid helped to modify prescribing behaviour in Northumberland]]></article-title>
<source><![CDATA[Bandolier: evidence-based health care]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Solpadol effervescent tablets SPC]]></article-title>
<source><![CDATA[Electronic Medicines Compendium]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coll de Tuero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dalfó]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de la Figuera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gibert]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Isnard]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Hipertensió arterial]]></source>
<year>2003</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Institut Català de la Salut]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McEntee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[What is the sodium content of medicines?]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Liverpool ]]></publisher-loc>
<publisher-name><![CDATA[North West Medicines Information Centre]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Annex to the European Commission guideline on &#8216;Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<collab>Dirección General de Farmacia y Productos Sanitarios</collab>
<article-title xml:lang=""><![CDATA[Excipientes de declaración obligatoria en el cartonaje y advertencias a incluir en el prospecto]]></article-title>
<source><![CDATA[Circular 16/98]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Circular nº 2/2008: Información sobre los excipientes en el etiquetado, prospecto y ficha técnica de los medicamentos de uso humano]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Úbeda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Llopico]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication]]></article-title>
<source><![CDATA[Pharmacoepidemiol Drug Saf]]></source>
<year>2009</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>417-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Majeed]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mackenzie]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[MacDonald]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2013</year>
<volume>347</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perrin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Berdot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pannier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Danchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Durieux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of exposure to effervescent drugs in a large health check-up population in France: a cross-sectional study]]></article-title>
<source><![CDATA[BMJ Ope]]></source>
<year>2018</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benítez-Camps]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vinyoles-Bargalló]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rebagliato-Nadal]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Morros-Pedrós]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pera-Pujadas]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dalfó-Baqué]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial]]></article-title>
<source><![CDATA[MC Cardiovasc Disord]]></source>
<year>2015</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benítez-Camps]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morros]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pera-Pujadas]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dalfó-Baqué]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bayó]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rebagliato]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of effervescent paracetamol on blood pressure: a crossover randomized clinical trial]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2018</year>
<volume>36</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1656-62</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chernova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistant Hypertension Updated Guidelines]]></article-title>
<source><![CDATA[Curr Cardiol Rep]]></source>
<year>2019</year>
<volume>21</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Calhoun]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Brook]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Daugherty]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Dennison-Himmelfarb]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2018</year>
<volume>72</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e53-90</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
